PS
PeptideScholar

Content reviewed by clinical research staff

Last reviewed: March 2026Sources: PubMed, FDA, WADA Prohibited List

Evidence graded using the PeptideScholar A-D system

AOD-9604

CPreclinical

Growth hormone fragment · 16 amino acids

Not FDA Approved

AOD-9604 is a modified fragment of human growth hormone (amino acids 176-191) originally developed for obesity treatment. It received GRAS status from the FDA for use in food products.

Mechanism of Action

Mimics the lipolytic fragment of growth hormone, stimulating fat breakdown while having no effect on IGF-1 levels or blood glucose. Does not exhibit the growth-promoting effects of full GH.

Benefits

  • Fat reduction without GH-related side effects in animal studies
  • GRAS status indicates food-grade safety assessment
  • No impact on insulin sensitivity or blood glucose
  • Does not promote tissue growth
Not Medical Advice — Research-Reported Information Only

This content is for informational purposes only and does not constitute medical advice.

AOD-9604 — Dosing in Published Research

Reported Routes: Subcutaneous injection, Oral
Phase 2 obesity trial used 1 mg SC daily. Limited clinical data available for dosing guidance.

The dosing information above is sourced from published research literature and clinical trials. These are not recommendations. Individual responses vary. Always consult a healthcare provider before considering any peptide-based therapy.

Side Effects

  • Limited human trial data
  • Mild headache reported
  • Injection site reactions
  • Uncertain long-term safety profile

Considering Peptide Research?

AOD-9604 is not FDA-approved. Always consult a licensed healthcare provider before considering any peptide.

Learn About Finding a Provider
Always Consult a Professional

Research & Evidence

AnimalEndocrinology, 2001

Metabolic effects of the GH fragment AOD9604

AOD-9604 stimulated lipolysis and inhibited lipogenesis in obese Zucker rats without affecting IGF-1

PMID: 11713213
RCTJournal of Endocrinology, 2004

Safety of AOD-9604 in obese subjects

Phase 2 trial showed good tolerability but modest weight reduction that did not reach statistical significance

PMID: 14764774

Compare AOD-9604 With

AOD-9604 vs Semaglutide
AOD-9604 vs Tirzepatide
AOD-9604 vs Ipamorelin

References

  1. 1. Metabolic effects of the GH fragment AOD9604. Endocrinology, 2001. “AOD-9604 stimulated lipolysis and inhibited lipogenesis in obese Zucker rats without affecting IGF-1” [PMID: 11713213]
  2. 2. Safety of AOD-9604 in obese subjects. Journal of Endocrinology, 2004. “Phase 2 trial showed good tolerability but modest weight reduction that did not reach statistical significance” [PMID: 14764774]

Recommended Resources

The Peptide Protocols Handbook

Evidence-based reference guide covering mechanisms, research, and clinical applications.

View on Amazon

Third-Party Peptide Testing

Independent lab analysis to verify peptide purity and authenticity.

Learn More

Links may be affiliate links. See our disclosure.

Medical Disclaimer

This content is for informational and educational purposes only and does not constitute medical advice, diagnosis, or treatment recommendations.

Always consult a qualified healthcare provider before starting, stopping, or modifying any treatment. Do not disregard professional medical advice based on information found on this site.

No claims of therapeutic efficacy are made for substances that are not FDA-approved for the discussed indications. Research citations reflect published findings and do not imply endorsement.

Get Peptide Research Updates

Weekly evidence summaries and regulatory alerts.

No spam. Unsubscribe anytime.